Targeted Oncology16h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Targeted Oncology2d
Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine
Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...
Medical Xpress3d
Specific long term condition combinations have major role in NHS 'winter pressures'
To try and find out, they reviewed routinely collected and linked primary and secondary care health data for adults in ...
Business Insider3d
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Key outcomes included: Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints ... in 2024 or early 2025 under the auspices of the ...
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
For more information about Cellectar, please visit Cellectar.com. To learn more about SpectronRx, visit SpectronRx.com.
'Moonlighting' enzymes may lead to new cancer therapies
Researchers at the Center for Genomic Regulation (CRG) reveal that metabolic enzymes known for their roles in energy ...